Results 1 to 10 of about 57 (45)

A review of fenfluramine for the treatment of Dravet syndrome patients [PDF]

Current Research in Pharmacology and Drug Discovery, 2022
Introduction: Dravet Syndrome (DS) is a rare epileptiform disorder typically presenting within the first year of life of a normally developing infant. It is characterized by several prolonged seizures that are often resistant to current anti-epileptic ...
Kayla Simon, Hunter Sheckley, Christopher L. Anderson, Zhao Liu, Paul R. Carney   +4 more
doaj   +2 more sources

Fenfluramine: a plethora of mechanisms? [PDF]

Frontiers in Pharmacology, 2023
Developmental and epileptic encephalopathies are rare, treatment-resistant epilepsies with high seizure burden and non-seizure comorbidities. The antiseizure medication (ASM) fenfluramine is an effective treatment for reducing seizure frequency ...
Jo Sourbron, Lieven Lagae
doaj   +2 more sources

Pharmacovigilance study on old drugs repurposed for rare diseases across different indications: the case of fenfluramine [PDF]

Frontiers in Pharmacology
ObjectiveAs an old drug with a new application in rare diseases with epileptic symptoms, fenfluramine may have potential unrecognized adverse events.
Jiahong Zhong, Zhuomiao Lin, Junling Xue, Xihui Yu   +3 more
doaj   +2 more sources

Resolution of Fenfluramine-associated pulmonary arterial hypertension in Lennox-Gastaut syndrome: A case report and literature review [PDF]

Epilepsy & Behavior Reports
Fenfluramine is a medication originally approved for weight loss before being withdrawn for an association with the development of pulmonary arterial hypertension (PAH) and cardiac valvulopathy.
Rebecca Strafella, Richard Wang, Marissa Petchpradub, Ariel Sacknovitz, Patricia E. McGoldrick, Steven M. Wolf   +5 more
doaj   +2 more sources

Fenfluramine HCl (Fintepla^® ) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study. [PDF]

Epilepsia, 2020
Abstract Objective Fenfluramine has been shown to provide clinically meaningful and statistically significant reductions in convulsive seizure frequency in children and adolescents (aged 2‐18 years) with Dravet syndrome in two randomized, placebo‐controlled clinical trials. The objective of this analysis was to assess longer‐term safety and efficacy of
Sullivan J, Scheffer IE, Lagae L, Nabbout R, Pringsheim M, Talwar D, Polster T, Galer B, Lock M, Agarwal A, Gammaitoni A, Morrison G, Farfel G.   +12 more
europepmc   +2 more sources

New medication for Lennox-Gastaut syndrome management

Педиатрическая фармакология, 2022
Управление по санитарному надзору за качеством пищевых продуктов и медикаментов США (FDA) одобрило пероральный раствор фенфлурамина (Fintepla) — лекарственное средство для лечения судорог, связанных с синдромом Леннокса - Гасто (СЛГ) — редкой формой ...
article Editorial
doaj   +1 more source

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. [PDF]

Pharmacoeconomics, 2023
Wijnen B, Witlox W, Wolff R, Fayter D, Ramaekers B, Otten T, Ryder S, Posadzki P, Worthy G, Stirk L, Armstrong N, Kleijnen J, Joore M.   +12 more
europepmc   +1 more source

The Quest for Secondary Pharmaceuticals: Drug Repurposing/Chiral-Switches Combination Strategy. [PDF]

ACS Pharmacol Transl Sci, 2023
D'Acquarica I, Agranat I.
europepmc   +1 more source

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes. [PDF]

Drugs, 2023
Frampton JE.
europepmc   +1 more source

A zebrafish-centric approach to antiepileptic drug development. [PDF]

Dis Model Mech, 2021
Baraban SC.
europepmc   +1 more source